This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 12
  • /
  • Meta-analysis of Victoza (liraglutide) trials demo...
Drug news

Meta-analysis of Victoza (liraglutide) trials demonstrates efficacy in type 2 diabetes- Novo Nordisk

Read time: 1 mins
Last updated:3rd Dec 2015
Published:3rd Dec 2015
Source: Pharmawand

New findings from a network meta-analysis show that treatment with Victoza (liraglutide), from Novo Nordisk, provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to SGLT-2 inhibitors in people with type 2 diabetes who are inadequately controlled with metformin alone or in combination with sulfonylurea, DPP-4 inhibitors or thiazolidinedione. The meta-analysis evaluated the relative efficacy of liraglutide to SGLT-2 inhibitors, including canagliflozin, empagliflozin and dapagliflozin.

In an analysis of 17 randomised controlled trials, liraglutide demonstrated greater reductions in mean HbA1c compared to all SGLT-2 inhibitors (placebo-adjusted mean change -1.01%/-1.18% for liraglutide 1.2 mg/1.8 mg; -0.64%/-0.79% for canagliflozin 100 mg/300 mg; -0.32%/-0.38% for dapagliflozin 5 mg/10 mg; -0.59%/-0.62% for empagliflozin 10 mg/25 mg). Findings were presented at the World Diabetes Congress of the International Diabetes Federation.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.